Patent application number | Description | Published |
20090186370 | DIAGNOSTIC BIOMARKERS FOR VASCULAR ANEURYSM - Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms. | 07-23-2009 |
20090214654 | TREATMENT OF ANEURYSM WITH APPLICATION OF CONNECTIVE TISSUE STABILIZATION AGENT IN COMBINATION WITH A DELIVERY VEHICLE - Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent from the delivery vehicle to the aneurysm. The connective tissue stabilization agent can be collagen stabilization agent, elastin stabilization agent, or a combination thereof. The aneurysm can be treated individually, simultaneously or sequentially with collagen stabilization agent and elastin stabilization agent embedded in separate delivery vehicles. | 08-27-2009 |
20090326575 | Embolic protection during percutaneous heart valve replacement and similar procedures - Various devices are described to provide filtering of flow from the aorta to the left carotid artery and the right carotid artery. The filters can be brought into a desired position through one or more peripheral arteries. A single filter device can provide the desired filtering or a plurality of devices can be used. In particular a single filter device can span between the brachiocephalic artery and the left carotid artery. These filter devices can be used effectively to capture emboli generated during procedures on the heart so that emboli do not travel to the patient's brain where the emboli can cause a stroke or other adverse event. In particular, these filters can be used during percutaneous procedures on the heart, such as endovascular heart valve replacement. | 12-31-2009 |
20100016833 | Devices for the Treatment of Vascular Aneurysm - Devices for the treatment of vascular aneurysms are described. The treatment is achieved through the delivery of an effective amount of elastin stabilization agent to an isolated volume at the aneurysm. The elastin stabilization agent maybe embedded in a delivery composition. The device optionally has an aspiration means to improve the effectiveness of the treatment. | 01-21-2010 |
20100119605 | COMPOSITIONS FOR TISSUE STABILIZATION - Collagen crosslinking/stabilization composition optionally in combination with elastin crosslinking composition as treatment of vascular aneurysms, methods of using the compositions, especially with respect to in vivo procedures are described. The treatment is achieved through the delivery of an effective amount of crosslinking/stabilization composition to the site of the aneurysm. The crosslinking/stabilization agent may be embedded in a delivery composition and delivered to the site of aneurysm using a delivery device. The site of the aneurysm may be isolated for treatment using the delivery device. The elastin stabilization agent may be simultaneously or sequentially delivered with the collagen crosslinking/stabilization agent for the treatment of vascular aneurysms in the isolated section of blood vessel. | 05-13-2010 |
20110081423 | Tissue Stabilization for Heart Failure - Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium, or a combination thereof using a catheter type of device with an attached reservoir. Controlled placement and release of the therapeutic composition can be achieved using a delivery vehicle to formulate the composition. | 04-07-2011 |
20110093000 | VASCULAR MEDICAL DEVICES WITH SEALING ELEMENTS AND PROCEDURES FOR THE TREATMENT OF ISOLATED VESSEL SECTIONS - Devices for the isolation of a selected portion of a vessel are described. In some embodiments, the device comprises an introducer sheath and a sealing catheter that are movable relative to each other to create an isolated volume with adjustable size and location. The methods for the treatment of vascular aneurysms using the devices are described. The treatment is achieved through the delivery of an effective amount of stabilization agent to an isolated volume that encompass the aneurysm. The device optionally has an aspiration means to improve the effectiveness of the treatment. | 04-21-2011 |
20110218517 | IN VIVO CHEMICAL STABILIZATION OF VULNERABLE PLAQUE - Procedures for the stabilization of vulnerable plaque can comprise identification of the vulnerable plaque and the delivery of a stabilization composition to the location of the vulnerable plaque. For example, the stabilization composition can be delivered to an isolated portion of the vessel with the vulnerable plaque and/or alternatively or additionally using a profusion balloon that delivers the stabilization composition at the vessel wall near the vulnerable plaque. Suitable stabilization compositions can comprise a collagen crosslinking agent, an elastin stabilization agent, VEGF or a combination thereof. Vascular endothelial growth factor (VEGF) can be used to encourage endothelialization of the vessel wall near the vulnerable plaque. | 09-08-2011 |
20110251629 | EMBOLECTOMY DEVICES AND METHODS FOR TREATMENT OF ACUTE ISCHEMIC STROKE CONDITION - Clot engagement element comprising bundle of unwoven fibers can be assembled to form an acute stroke treatment device. The device has the capability of forming a three dimensional filtration matrix comprising effective pores with a distribution of sizes. The bundle of fiber design allows the device to be effectively delivered into circuitous cerebral arteries to remove clot that causes stroke. The fiber bundle based filtration matrix offers the advantages of conforming to the changing inner perimeter of a blood vessel during a clot removal process and thus the capability to effectively retain and remove a clot in the vessel. The filtration matrix offers the additional advantage to trap any break-off of the clot during the removal process. A plurality of fiber bundles can be combined to form an effective clot engagement element. Supplemental engagement structure as well as mechanical treatment structure can be integrated into the stroke treatment device. The deployment of the fiber based elements can be facilitated by actuation tool. Aspiration can be employed during the clot removal process. | 10-13-2011 |
20110313445 | EMBOLIC PROTECTION DURING PERCUTANEOUS HEART VALVE REPLACEMENT AND SIMILAR PROCEDURES - Various devices are described to provide filtering of flow from the aorta to the left carotid artery and the right carotid artery. The filters can be brought into a desired position through one or more peripheral arteries. A single filter device can provide the desired filtering or a plurality of devices can be used. In particular a single filter device can span between the brachiocephalic artery and the left carotid artery. These filter devices can be used effectively to capture emboli generated during procedures on the heart so that emboli do not travel to the patient's brain where the emboli can cause a stroke or other adverse event. In particular, these filters can be used during percutaneous procedures on the heart, such as endovascular heart valve replacement. | 12-22-2011 |
20120150211 | EMBOLIC PROTECTION DURING PERCUTANEOUS HEART VALVE REPLACEMENT AND SIMILAR PROCEDURES - Various devices are described to provide filtering of flow from the aorta to the left carotid artery and the right carotid artery. The filters can be brought into a desired position through one or more peripheral arteries. A single filter device can provide the desired filtering or a plurality of devices can be used. In particular a single filter device can span between the brachiocephalic artery and the left carotid artery. These filter devices can be used effectively to capture emboli generated during procedures on the heart so that emboli do not travel to the patient's brain where the emboli can cause a stroke or other adverse event. In particular, these filters can be used during percutaneous procedures on the heart, such as endovascular heart valve replacement. | 06-14-2012 |
20120197284 | DEVICES, THERAPEUTIC COMPOSITIONS AND CORRESPONDING PERCUTANEOUS TREATMENT METHODS FOR AORTIC DISSECTION - The methods and devices disclosed herein pertain to the percutaneous treatment of various forms of aortic dissection by at least partially filling the false lumen of the aortic dissection with a stabilization agent percutaneously and steps to decrease the size of the false lumen using the devices. Fluid maybe aspirated from the false lumen to decrease the volume of the false lumen. And the entrance opening between the true lumen and the false lumen may be sealed with a sealing agent such as a biocompatible adhesive. The medical devices disclosed herein generally comprise an extendable sealing element that is used in conjunction with a catheter to expand the true lumen while reducing the size of the false lumen. The device has the ability to aspirate and/or deliver fluid containing the stabilization agent into the false lumen. | 08-02-2012 |
20120323211 | Coated Balloons for Blood Vessel Stabilization - A coated balloon device for stabilizing a section of a blood vessel in a living subject is disclosed. The coating layer of the coated balloon comprises a phenolic compound having a plurality of phenolic groups connected to form a hydrophobic core with peripheral phenolic hydroxyl groups. The coating layer of the coated balloon may contain a hydrophilic polymer to facilitate the release of the phenolic compound. The balloon in general is made of a compliant polymer for atraumatic contact with the blood vessel. In some embodiments, the coating of the coated balloon device further comprises a hydrophilic undercoat layer between the balloon and the coating layer. In some embodiments, the coated balloon device further comprises a sacrificial top coating that dissolves upon delivery into the section of the blood vessel and comprises a hydrophilic composition including sugar, sugar derivatives, or a combination thereof. | 12-20-2012 |
20130184742 | AORTIC ARCH FILTRATION SYSTEM FOR CAROTID ARTERY PROTECTION - Filtration systems with integrated filter element(s) forming portions of the wall of the filtration catheter are disclosed. The filtration catheters disclosed herein are designed to be used alone or in conjunction with another filter device to provide embolic protection of both carotid arteries. Occlusive element such as balloon is placed on the exterior of the filtration catheter to redirect blood flow in the vessels during the filtration process as well as to help anchor the filtration catheter inside the vessel. The integrated filter element(s) does not require collapsing thus significantly reduces the complexity of the filtration system retrieval process and the chances of releasing emboli back into the blood stream. The compact design of the filtration systems makes them particularly suitable for embolic protection during endovascular procedures on or close to the heart. | 07-18-2013 |
20130245552 | VASCULAR MEDICAL DEVICES WITH SEALING ELEMENTS AND PROCEDURES FOR THE TREATMENT OF ISOLATED VESSEL SECTIONS - Devices for the isolation of a selected portion of a vessel are described. In some embodiments, the device comprises an introducer sheath and a sealing catheter that are movable relative to each other to create an isolated volume with adjustable size and location. The methods for the treatment of vascular aneurysms using the devices are described. The treatment is achieved through the delivery of an effective amount of stabilization agent to an isolated volume that encompass the aneurysm. The device optionally has an aspiration means to improve the effectiveness of the treatment. | 09-19-2013 |
20130253429 | MEDICAL DEVICES TO FACILITATE TISSUE STABILIZATION FOR HEART FAILURE - Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium, or a combination thereof using a catheter type of device with an attached reservoir. Controlled placement and release of the therapeutic composition can be achieved using a delivery vehicle to formulate the composition. | 09-26-2013 |
20130273580 | ELISA ASSAY KIT, ELISA FOR DETERMINING DESMOSINE LEVELS FROM URINE SAMPLES AND DIAGNOSTIC URINE ASSAYS FOR ANEURYSMS - Improved ELISA assay formats are described that provide for effective measurement of desmosine, an elastin degradation product, in urine samples. The urine samples can be effectively introduced into the assay with little or no sample preparation. The competitive ELISA assay based on high titer polyclonal antibodies is suitable for commercial application. Desirable antibodies can be generated using desmosine bound to a protein or the like using a protein crosslinking agent. The desmosine assay are found to be useful for the diagnosis of aortic aneurysms in which desmosine levels of patients with aortic aneurysms have been found to be significantly elevated relative to a control group. | 10-17-2013 |